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unfamiliar with the management of 
Addison’s disease and FMS and wanted 
to ensure that the patient was managing 
their medication regimen appropriately.
During the HMR interview, the patient 
demonstrated a reasonable knowledge 
of her medical conditions and the 
role of her medications in managing 
them. She was very willing to take 
her medications as prescribed, but 
described significant issues with 
remembering whether or not she had 
taken them. Consequently, she would 
frequently take doses of thyroxine and 
cortisone mid‑morning if she could not 
recall having taken them earlier in the 
morning. She recalled that a GP had 
once investigated her poor memory via 
imaging and numerous blood tests, but 
no apparent cause was identified.
She described her most concerning 
medical issue as poorly controlled 
pain due to FMS. Whilst she found 
that amitriptyline helped with this 
pain, even very low doses resulted in 
substantial sedation and grogginess the 
following day. This case study discusses 
the considerations that were made in 
selecting an appropriate management 
option for pain associated with FMS in 
this patient.
Case details
A 47‑year‑old woman was referred for a Home Medicines Review 
(HMR) in March 2013. Her medical history included Addison’s disease, 
endometriosis, fibromyalgia (FMS), hypothyroidism and osteopenia. 
Her current prescribed medications were as follows:
•	 Amitriptyline 5 mg (1/2 x 10 mg 
tablet) at night when required for 
insomnia (used once every three to 
four months).
•	 Cortisone acetate 25 mg in the 
morning and 12.5 mg at night.
•	 Fludrocortisone 100 microgram in the 
morning.
•	 Hydrocortisone 100 mg for injection 
when required for Addisonian crisis.
•	 Methylprednisolone aceponate 0.1% 
ointment applied daily when required.
•	 Naproxen 275 mg when required for 
pain associated with endometriosis 
(purchased over the counter).
•	 Paracetamol 500 mg when required 
for headache.
•	 Thyroxine 50 microgram in the 
morning.
She had recently moved to the area 
and no laboratory/pathology results 
were available prior to undertaking 
the HMR. Her new general practitioner 
(GP) requested the HMR as she was 
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LEARNING OBJECTIVES
After reading this article, pharmacists should be 
able to:
•	 Describe the signs and symptoms of 
fibromyalgia
•	 Evaluate management options for pain 
associated with fibromyalgia 
•	 Formulate a management plan for patients with 
pain associated with fibromyalgia.
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Clinical assessment and 
review issues
Overview of FMS
FMS is a condition common in 
middle‑aged adults, particularly women.1 
It is characterised by the gradual onset 
of widespread musculoskeletal pain 
that is often described as a deep and 
burning ache, frequently coexisting with 
disturbed sleep and fatigue. Symptoms 
usually stabilise within the first year of 
onset and remain largely unchanged 
over time.1 
The legitimacy of FMS as a medical 
disorder was questioned for many years 
by some clinicians due to its seemingly 
unrelated symptoms and the lack of 
an identifiable cause.2 However, it is 
now recognised as a common, chronic, 
widespread pain disorder resulting from 
apparent neurochemical imbalances 
in the central nervous system. Whilst 
the aetiology and pathogenesis 
of FMS remain uncertain, multiple 
neurophysiological mechanisms appear 
to be involved, and the disorder is 
thought to primarily be caused by 
dysfunctional processing of pain in the 
central nervous system.3 This results in a 
‘central amplification’ of pain perception 
in people with FMS, characterised by 
phenomena such as allodynia (pain 
due to a stimulus that is not normally 
pain‑ provoking) and hyperalgesia (an 
increased response to painful stimuli).2
A definitive diagnostic laboratory 
test is yet to be developed for FMS; 
it is generally diagnosed via criteria 
that include measures of widespread 
body pain in addition to coexisting 
conditions such as fatigue, trouble 
thinking, depression, abdominal 
pain and headache.4 An important 
consideration in the diagnosis of FMS is 
that many of the symptoms are similar 
to a number of rheumatologic and 
non‑rheumatologic disorders (Table 1).3 
It is notable that the patient discussed 
in this case study also had Addison’s 
disease and hypothyroidism, both of 
which are differential diagnoses for 
FMS.3 Consequently, it was apparent 
that appropriate management of these 
conditions would minimise the potential 
for them to adversely impact upon 
the severity of her FMS.5 Conversely, 
the skeletal effects of excessive doses 
of cortisone and thyroxine would 
accelerate her bone mineral density 
(BMD) loss,6 so resolving her compliance 
issues became a high priority in 
this HMR.
The memory issues described by 
the patient reviewed in this HMR are 
not uncommon in people with FMS. 
It has been reported that cognitive 
impairment is a common manifestation 
of FMS, with up to 80% of people with 
the disorder showing measurable 
declines in working memory, attention 
and executive functions.7 The level of 
pain associated with FMS may correlate 
with the degree of memory impairment, 
with some studies reporting that more 
severe pain is associated with poorer 
memory function.7 Consequently, 
it is possible that improved pain 
management in this patient would 
also potentially alleviate some of her 
memory issues.
Managing FMS
There is currently no cure for FMS. 
For most patients, the goals of 
treatment are to alleviate pain, increase 
restorative sleep, and improve physical 
function by reducing associated 
symptoms.8 Possibly due to the 
diversity of symptoms associated 
with FMS, no single therapy has been 
found to improve all manifestations 
of the syndrome. Furthermore, as the 
condition is heterogeneous in nature, 
ideal management utilises a patient‑
tailored multimodal approach that 
combines non‑pharmacologic and 
pharmacologic treatments.9 
Non‑pharmacological interventions 
that may benefit patients with FMS, 
include8–10:
•	 education to improve self‑efficacy and 
coping mechanisms
•	 exercise (such as aquatic exercises and 
tai chi; the most studied modalities 
are aerobic or mixed‑type exercises 
involving aerobic, strength and/or 
flexibility routines)
Rheumatologic disorders Non-rheumatologic disorders
•	 Rheumatoid arthritis
•	 Systemic lupus erythematosus 
•	 Ankylosing spondylitis
•	 Polymyalgia rheumatica 
•	 Sjögren’s syndrome 
•	 Polyarticular osteoarthritis 
•	 Crystal-induced arthritis 
•	 Drug-induced lupus 
•	 Inflammatory myositis 













•	 Post-traumatic stress disorder
•	 Somatisation disorders
Table 1. Differential diagnosis of FMS (Reproduced from Han et al.)3
“FOR MOST PATIENTS, THE GOALS OF 
TREATMENT ARE TO ALLEVIATE PAIN, 
INCREASE RESTORATIVE SLEEP, AND 
IMPROVE PHYSICAL FUNCTION BY 
REDUCING ASSOCIATED SYMPTOMS.”
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•	 acupuncture, with or without 
electrical stimulation
•	 balneotherapy (bathing in water 
without exercise)
•	 psychological interventions 
(for example, cognitive behavioural 
therapy). 
There is no definitive evidence that any 
of these interventions is superior to 
the others, and the effect is generally 
modest.9 However, they can be valuable 
adjuncts to pharmacological treatments, 
particularly education and coping skills.9 
Pharmacological management of FMS 
generally involves symptom‑based 
treatment. Several classes of agents may 
be employed, including antidepressants, 
non‑steroidal anti‑inflammatory 
drugs (NSAIDs), opioids, sedatives, 
muscle relaxants, hypnotics and 
anticonvulsants.3 With regards to pain 
management, there is no definitive 
evidence from clinical trials to guide the 
selection of agent/s. There is greatest 
evidence for tricyclic antidepressants 
(TCAs), selective serotonin reuptake 
inhibitors (SSRIs), duloxetine and 
pregabalin.3 Antidepressants tend to be 
effective regardless of whether mood 
disturbance is present. Low doses of 
TCAs, particularly amitriptyline, are most 
frequently utilised in the management 
of FMS, and are effective in treating 
the sleep disturbances, pain and 
depressive symptoms associated with 
the condition.3 However, these agents 
are effective for only about 40% of 
patients, and generally result in greater 
improvements in sleep quality than 
pain. Furthermore, they may exacerbate 
fatigue and cognitive dysfunction,7 
which are important considerations in 
the patient reviewed in this HMR. 
SSRIs and duloxetine have also been 
reported to reduce pain associated 
with FMS, and are generally better 
tolerated than TCAs.8 Milnacipran 
(Joncia), a SNRI with increased selectivity 
for noradrenaline than serotonin, 
is considered to be the most beneficial 
agent in patients with FMS‑associated 
cognitive dysfunction.8 However, 
this agent is not PBS listed in Australia. 
Of the anticonvulsants, pregabalin is 
the most studied in FMS.3 It has been 
found to reduce pain and improve both 
sleep and quality of life,3 although it 
may cause significant negative effects 
on cognition.7 
In terms of NSAIDs and analgesics, 
ibuprofen and naproxen have been 
found to be no more effective than 
placebo in treating pain associated with 
FMS, although they may augment the 
effect of TCAs and anticonvulsants.8 
Despite this limited efficacy, the majority 
of patients with FMS perceive greater 
pain relief from NSAIDs compared to 
paracetamol.8 Opioids are generally not 
recommended for managing FMS due 
to limited efficacy and their potential 
for dependency, although tramadol has 
been shown to be effective in relieving 
FMS‑associated pain and improving 
sleep quality.8
It is important to acknowledge that 
many of the agents used to treat 
FMS‑associated pain may exacerbate 
other symptoms associated with the 
syndrome.11 Fatigue may be aggravated 
by anticonvulsants, antidepressants or 
opioids; depression may be exacerbated 
by opioids; gastrointestinal symptoms 
may be affected by NSAIDs, opioids and 
antidepressants; and sleep disturbance 
may be aggravated by opioids and 
antidepressants.11 Consequently, it is 
important to monitor for both efficacy 
and adverse effects once a drug 
treatment has been initiated. 
As FMS is a chronic condition and 
conventional treatments are of 
limited benefit, many patients 
may use complementary and 
alternative medicines to manage it.12 
Unfortunately, there is little evidence 
that complementary medicines are 
of substantial benefit in treating 
the symptoms of FMS. Creatine 
supplementation was recently reported 
to slightly improve muscle function 
but not other features of FMS;13 other 
trials have investigated St John’s 
Wort, Cat’s Claw, Devil’s Claw, oral 
anthocyanidin and topical capsaicin.12 
However, a recent review concluded 
that there is insufficient evidence for any 
herbal medicine as a treatment of FMS,12 




In this HMR the patient’s primary 
concern was poorly managed pain 
associated with FMS. In consideration 
of the available literature and this 
patient’s poor tolerance of amitriptyline, 
it was recommended to cease 
amitriptyline and trial duloxetine. 
This was based on duloxetine having a 
lower potential to adversely affect her 
cognitive function than alternatives 
such as pregabalin and alternative 
TCAs.8 As patients with FMS frequently 
report considerable sensitivity to 
pharmacological treatments,9 a starting 
dose of 30 mg duloxetine once daily 
was suggested to reduce the risk of 
adverse effects.8 The patient was also 
encouraged to commence a gentle 
exercise regimen and was intent upon 
reviewing behavioural techniques with 
a psychologist following a discussion 
of the benefits of these during the 
HMR interview.
Several recommendations were 
also made to improve the patient’s 
compliance issues. She was encouraged 
to first trial a Dosette box to avoid 
doubling up on doses throughout the 
day. If this was proved ineffective, it was 
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“IT IS IMPORTANT TO 
ACKNOWLEDGE THAT MANY 
OF THE AGENTS USED TO TREAT 
FMS-ASSOCIATED PAIN MAY 
EXACERBATE OTHER SYMPTOMS 
ASSOCIATED WITH THE 
SYNDROME.”
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1. Which ONE of the following signs or 




c) Elevated serum C-reactive protein. 
d) Poor memory.
2. Which ONE of the following 
statements regarding fibromyalgia is 
the LEAST appropriate?
a) It is most common in middle-aged 
women.
b) Symptoms usually resolve around a year 
after onset. 
c) Disturbed sleeping patterns is a 
common manifestation.
d) Associated with inappropriate central 
pain processing. 
3. Which ONE of the following 
medicines is MOST effective in 





d) No medication is definitively more 
effective than another.
4. A 55 year old man has a medical 
history of significant depression and 
hypertension. He is newly diagnosed 
with fibromyalgia, and describes 
pain and insomnia as his most 
concerning symptoms. His current 
medications are sertraline 100 mg 
and quinapril 20 mg, both once daily 
in the morning. His blood pressure is 
well controlled and his mood is good 
despite his recent diagnosis.
Which ONE of the following 
recommendations is the LEAST 
appropriate for this man at this time?
a) Referral to a psychologist for education 
about self-efficacy and coping 
mechanisms.
b) Commence a trial of pregabalin to 
improve his pain and sleep.
c) Encouragement to commence a gentle 
exercise program if he leads a sedentary 
lifestyle.
d) Sertraline should be changed to a low 














recommended to consider two changes 
to her medication regimen to simplify it: 
•	 moving the thyroxine to a 
single, possibly supervised, once 
weekly dose14 
•	 changing twice daily cortisone to 
once daily prednisolone, although 
there is increasing evidence this may 
confer a higher risk of long‑term 
adverse metabolic effects compared 
with cortisone.15 
A final recommendation about 
managing this patient’s FMS was to 
consider checking her vitamin D level. 
This was due to there being some 
evidence that FMS is a risk factor 
for hypovitaminosis D, which may 
negatively impact upon her cognition.7 
Additionally, her coexisting osteopenia 
was likely to benefit from an adequate 
level of vitamin D and calcium intake.
OUTCOMES
At the time of writing, the patient had 
ceased amitriptyline and was taking 
30 mg duloxetine twice daily with 
limited improvement in FMS‑associated 
pain. However, cost was becoming an 
issue for her as duloxetine is neither 
licenced nor PBS‑subsidised for FMS in 
Australia (although it is FDA‑approved 
for this indication in the United States).8 
If the cost became prohibitive, her GP 
intended to switch her to a cheaper 
SSRI. Whilst she did not believe that her 
memory had improved, she was using a 
Dosette box and was confident that she 
was no longer doubling up on doses of 
her medications.
This case is an example of the 
complexities involved in the therapeutic 
decision‑making process undertaken by 
pharmacists in HMRs. It highlights how 
a patient’s concerns must be addressed 
within the context of their coexisting 
conditions, medication regimen, social 
circumstances and medication‑taking 
behaviour.
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